ASRT

Assertio Holdings, Inc.

Stock XETRA – Stock Market Prices, News & Analysis

Assertio Holdings, Inc. is a pharmaceutical company specializing in the marketing of drugs for various therapeutic segments, including pain and chronic diseases.

€ 9.17

Assertio Holdings, Inc.

9.17
ASRT

Assertio Holdings, Inc. is a pharmaceutical company specializing in the marketing of drugs for various therapeutic segments, including pain and chronic diseases.

Price history of Assertio Holdings, Inc.
Price history of Assertio Holdings, Inc.

Performance & Momentum

6 Months 0.99 %
1 Year 1.69 %
3 Years 12.87 %
5 Years 4.43 %

Strategic Analysis

Assertio Holdings, Inc. • 2026

Assertio Holdings positions itself as a niche pharmaceutical player, focusing on the commercialization of medications targeting pain and chronic diseases, which enables it to address high-demand therapeutic segments. Its business model relies on leveraging marketed products with a concentrated portfolio, thereby maximizing the effectiveness of its marketing and sales resources.

Strengths
  • Clear positioning in essential and persistent therapeutic segments
  • Focus on commercialization with a targeted product portfolio
  • Exposure to a robust and dynamic American healthcare market
Weaknesses
  • Limited portfolio in terms of product diversification
  • Dependence on pharmaceutical regulation and approval cycles
Momentum

The activity exhibits moderate momentum, demonstrating relative resilience despite a marked competitive context. The absence of recent news highlights a stability without major catalysts, inviting vigilance regarding the future evolution of the pipeline or commercial strategy.

Similar stocks to Assertio Holdings, Inc.

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone